Radioimmunoassay of drugs and its clinical application

  • G. P. Mould
  • G. W. Aherne
  • B. A. Morris
  • J. D. Teale
  • V. Marks
Review Papers


Recent developments in the production of antisera for use in immunoassays are discussed and their incorporation into drug radioimmunoassay techniques are reviewed. The contribution of the results from such assays to our knowledge of the pharmacokinetics and metabolism of particular groups of compounds is evaluated.

Key words

Antisera drugs radioimmunoassay pharmacokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. (1).
    Marks, V., Lindup, W.E. and Bayliss, E.M. (1973): Measurements of therapeutic agents in blood. Adv. Clin. Chem.,76, 47–109.CrossRefGoogle Scholar
  2. (2).
    Alexanderson, B., Price-Evans, D.A. and Sjöqvist, F. (1969): Steady—state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Brit. Med. J.,4, 764–768.CrossRefPubMedGoogle Scholar
  3. (3).
    Braithwaite, R.A. and Flanagan, R.J. (1975): Steady —state plasma nortriptyline concentrations in epileptic patients. Brit. J. Clin. Pharmacol.,2, 469470.Google Scholar
  4. (4).
    Aherne, G.W., Mould, G.P., Piall, E. and White, W.F. (1977): Prolonged and increased methotrexate concentrations using probenecid in man. Brit. Med. J., (In press).Google Scholar
  5. (5).
    Trevor, A., Rowland, M. and Way, EX. (1971): Techniques for studying drug decompositionin vivo, in Fundamentals of drug metabolism and drug disposition, eds. La Du, B.N., Mandel, H.G. and Way, EX., 369–399, Williams & Wilkins, Baltimore.Google Scholar
  6. (6).
    Curry, S.H. (1968): Determination of nanogram quantities of chlorpromazine and some of its metabolites in plasma using gas-liquid chromatography with an electroncaptive detector. Analyt. Chem.,40, 1251–1256.CrossRefGoogle Scholar
  7. (7).
    Kabra, P.M. and Marton, L.J. (1976): Determination of carbamazepine in blood or plasma by high-pressure liquid chromatography. Clin. Chem.,22, 1070–1072.PubMedGoogle Scholar
  8. (8).
    Shaw, E.J., Watson, A., Landon, J. and Smith, D.S. (1977): Estimation of serum gentamicin by quenching fluorimmunoassay. J. Clin. Path.,30, 526–531.CrossRefPubMedGoogle Scholar
  9. (9).
    Broughton, A. and Strong, J.E. (1976): Radioimmunoassay of antibiotics and chemotherapeutic agents. Clin. Chem.,22, 726–732.PubMedGoogle Scholar
  10. (10).
    Aherne, G.W., Piall, E. and Marks, V. (1976): The radioimmunoassay of tricyclic antidepressants. Brit. J. Clin. Pharmacol., J,3, 561–565.Google Scholar
  11. (11).
    Butler, Jr., V.P. (1975): Drug Immunoassay. J. Immunol. Methods,7, 1–21.CrossRefPubMedGoogle Scholar
  12. (12).
    Spector, S. (1973): Radioimmunoassay. Ann. Rev. Pharmacol.,13, 359–370.CrossRefPubMedGoogle Scholar
  13. (13).
    Landon, J. and Moffat, A.C. (1976): The radioimmunoassays of drugs. Analyst,101, 225–243.CrossRefPubMedGoogle Scholar
  14. (14).
    Marks, V., Morris, B.A. and Teale, J.D. (1974): Pharmacology. Brit. Med. Bull.,30, 80–86.PubMedGoogle Scholar
  15. (15).
    Landsteiner, K. (1946): In The Specificity of Serological Reactions, Harvard University Press, Cambs, Mass.Google Scholar
  16. (16).
    Erlanger, B.F., Borek, F., Beiser, B.M. and Lieberman, S. (1957): Steroid—protein conjugates 1. Precipitation and characterisation of conjugates of bovine serum albumin with progesterone, deoxycorticosterone and estrone. J. Biol. Chem.,234, 1090–1094.Google Scholar
  17. (17).
    Levine, L. and Powers, E. (1974): Radioimmunoassay for methotrexate. Res. Comm. Chem. Path. Pharmacol.,9, 543–554.Google Scholar
  18. (18).
    Aherne, G.W., Piall, E. and Marks, V. (1977): The radioimmunoassay of methotrexate. Brit. J. Cancer,36, 608–617.PubMedGoogle Scholar
  19. (19).
    Robinson, J.D., Morris, B.A., Piall, E.M., Aherne, G.W. and Marks, V. (1975): The use of rats in the screening of drug-protein conjugates for immunoreactivity in “Radioimmunoassay in Clinical Biochemistry”, Ed., Pasternak, C.A., 101-111. Heyden & Son Ltd., London.Google Scholar
  20. (20).
    Cheng, L.T., Kim, S.Y., Chung, A. and Castro, A. (1973): Amphetamines: New Radioimmunoassay. FEBS Letts.,36, 339–342.CrossRefGoogle Scholar
  21. (21).
    Tiegelaar, R.E., Rapport, II, R.L., Inman, J.K. and Kupferberg, H.J. (1973): A radioimmunoassay for diphenylhydantoin. Clin. Chim. Acta,43, 231–241.CrossRefGoogle Scholar
  22. (22).
    Spector, S. and Parker, C.W. (1970): Morphine: Radioimmunoassay. Science,168, 1347–1348.CrossRefPubMedGoogle Scholar
  23. (23).
    Oliver, Jr., G.C., Parker, B.M., Brasfield, D.L. and Parker, C.W. (1968): The measurement of digitoxin in human serum by radioimmunoassay. J. Clin. Invest.,47, 1035–1042.PubMedGoogle Scholar
  24. (24).
    Robinson, J.D., Morris, B.A., Aherne, G.W. and Marks, V. (1975): Development of radioimmunoassay for anticonvulsant drugs. J. Endocrinol.,64, 7–8.CrossRefGoogle Scholar
  25. (25).
    Robinson, J.D., Aherne, G.W., Teale, J.D., Morris, B.A. and Marks, V. (1975): Problems encountered in the use of radioiodination tags in radioimmunoassay for drugs. In “Radioimmunoassay in Clinical Biochemistry”, ed. Pasternak, C.A., 113–123, Heydon & Sons Ltd., London.Google Scholar
  26. (26).
    Rubenstein, K.E., Schneider, R.S. and Ullman, E.F. (1972): “Homogenous” enzyme immunoassay. A new immunochemical technique. Biochem. Biophys. Res. Commun.47, 846–851.CrossRefGoogle Scholar
  27. (27).
    Mule, S.J., Bastos, M.L. and Jukofsky, D. (1974): Evaluation of immunoassay for detection, in urine, of drugs subject to abuse. Clin. Chem.,20, 243–248.PubMedGoogle Scholar
  28. (28).
    Booker, H. and Darcey, B. (1975): Enzymatic immunoassay vs. gas/liquid chromatography for determination of phenobarbital and diphenylhydantoin in serum. Clin. Chem.,21, 1766–1768.PubMedGoogle Scholar
  29. (29).
    Albassam, M.N., Marks, V. and O’Sullivan, M. (1977): Enzyme immunoassay for nortriptyline: Conjugation of desmethylnortriptyline to β-D-galactosidase by dimethyl adipimidate and its use for immunoassay. (In preparation).Google Scholar
  30. (30).
    Belsey, R., De Luca, H.F. and Potts, Jr., J.T. (1971): Competitive binding assay for vitamin D and 25-OH vitamin D J. Clin. Endocrinol. Metab.,33, 554–557.CrossRefGoogle Scholar
  31. (31).
    Langone, J.J., Van Vunakis, H. and Bachur, N.R. (1975): Adriamycin metabolites: separation by high pressure liquid chromatography and quantitation by radioimmunoassay. Biochem. Med.,12, 283–289.CrossRefPubMedGoogle Scholar
  32. (32).
    Jarrott, B. and Spector, S. (1977): Development of a radioimmunoassay for clonidine. Fed. Proc,36, 949.Google Scholar
  33. (33).
    Clark, B.R., Tower, B.B. and Rubin, R.T. (1977): Radio-immunoassay of haloperidol in human serum. Life Sci.,20, 319–326.CrossRefPubMedGoogle Scholar
  34. (34).
    Huffman, D.H. (1975): Relationship between digoxin concentrations in serum and saliva. Clin. Pharmacol. Ther.,17, 310–312.PubMedGoogle Scholar
  35. (35).
    Gram, L.F. and Overø, K.F. (1974): First-pass metabolism of nortriptyline in man. Clin. Pharmacol. Ther.,18, 305–329.Google Scholar
  36. (36).
    Mould, G.P. (1977): An intestinal mixed-function oxidase system of potential importance in biopharmacy. Ph. D. Thesis, University of London.Google Scholar
  37. (37).
    Braithwaite, R.A. and Widdop, B. (1971): A specific gas-chromatographic method for the measurement of “steady-state” plasma levels of amitriptyline and nortriptyline in patients. Clin. Chim. Acta,35, 461–472.CrossRefPubMedGoogle Scholar
  38. (38).
    Gifford, L.A., Turner, P. and Pare, C.M.B. (1975): Sensitive method for the routine determination of tricyclic antidepressants in plasma using a specific nitrogen detector. J. Chromatogr.,105, 107–113.CrossRefPubMedGoogle Scholar
  39. (39).
    Belvedere, G., Burt, L., Frigero, A. and Pantarotto, C. (1975): Gas-chromatographic—mass fragmentographic determination of “steady-state” plasma levels of imipramine and desipramine in chronically treated patients. J. Chromatogr.,11, 313–321.CrossRefGoogle Scholar
  40. (40).
    Aherne, G.W., Marks, V., Mould, G.P. and Stout, G. (1977): A rapid sensitive radioimmunoassay method for measuring plasma nortriptyline and amitriptyline. Lancet,1, 1214.CrossRefPubMedGoogle Scholar
  41. (41).
    Smith, T.W., Butler, Jr., V.P. and Haber, E. (1969): Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay. New Engl. J. Med.,281, 1212–1216.CrossRefPubMedGoogle Scholar
  42. (42).
    Smith, T.W. and Haber, E. (1971): The clinical value of serum digitalis glycoside concentrations in the evaluation of drug toxicity. Ann. N.Y. Acad. Sci.,179, 322–337.CrossRefPubMedGoogle Scholar
  43. (43).
    Smith, T.W. (1970): Radioimmunoassay for serum digitoxin concentration: methodology and clinical experience. J. Pharmacol. Exp. Ther.,175, 352–360.PubMedGoogle Scholar
  44. (44).
    Zeegers, J.W., Maas, A.H.J., Willebrandts, A.F., Kryswijk, H.H. and Jambroes, G. (1973): The radioimmunoassay of plasma-digoxin. Clin. Chim. Acta,44, 109–117.CrossRefPubMedGoogle Scholar
  45. (45).
    Ravel, R. (1975): Negligible interference by spironolactone and prednisone in digoxin radioimmunoassay. Clin. Chem.,21, 1801–1803.PubMedGoogle Scholar
  46. (46).
    Unpublished data.Google Scholar
  47. (47).
    Smith, T.W. and Haber, E. (1973): Clinical value of the radioimmunoassays of the digitalis glycosides. Pharmacol. Rev.,25, 219–228.PubMedGoogle Scholar
  48. (48).
    Lader, S.R., Court, G., Johnson, B.F. and Hum, B.A.L. (1972): Radioimmunoassay of digoxin with iodinated tracer. Scand. J. Clin. Lab. Invest.,29, Suppl. 126, 14.10.Google Scholar
  49. (49).
    Jelliffe, R.W., Buell, J. and Kalaba, R. (1972): Reduction of digitalis toxicity by computer-assisted glycoside dosage regimens. Ann. Intern. Med.,77, 891–906.PubMedGoogle Scholar
  50. (50).
    Koch-Weser, J., Duhme, D.W. and Greenblatt, D.J. (1974): Influence of serum digoxin concentration measurements on frequency of digitoxicity. Clin. Pharmacol. Ther.,16, 284–287.PubMedGoogle Scholar
  51. (51).
    Aronson, J.K. (1975): The application of digoxin radioimmunoassay in monitoring drug therapy. In “Radioimmunoassay in Clinical Biochemistry”, ed. Pasternak,C.A., 91–100, Heyden & Sons Ltd., London.Google Scholar
  52. (52).
    Ingelfinger, J.A. and Goldman, P. (1976): The serum digitalis concentration-does it diagnose digitalis toxicity. N. Engl. J. Med.294, 867–870.CrossRefPubMedGoogle Scholar
  53. (53).
    Lukas, D.S. (1971): Some aspects of the distribution and disposition of digitoxin in man. Ann. N.Y. Acad. Sci.,779, 338–359.CrossRefGoogle Scholar
  54. (54).
    Teale, J.D., Clough, J.M. and Marks, V. (1977): Radioimmunoassay of vinblastine and vincristine. Brit. J. Clin. Pharmacol.,4, 169–172.Google Scholar
  55. (55).
    Farber, S., Diamont, L.K., Mercer, R.D., Sylvester, R.F. and Wolff, J.A. (1948): Temporary remissions in acute leukaemia in children produced by folic acid antagonist, 4-aminopteroylglutamic acid (Aminopterin). New Engl. J. Med.,238, 787–793.CrossRefPubMedGoogle Scholar
  56. (56).
    Frei III, E., Jaffe, N., Tattersall, M.H.N., Pitman, S. and Parker, L. (1975): New approaches to cancer chemotherapy with methotrexate. New Engl. J. Med.,293, 846–851.CrossRefGoogle Scholar
  57. (57).
    Huffman, D.F., Wan, S.H., Azarnoff, D.L. and Hoogstraten, B. (1973): Pharmacokinetics of methotrexate. Clin. Pharmacol. Ther.,14, 572–579.PubMedGoogle Scholar
  58. (58).
    Freeman, H.J. (1957): Fluorimetric method for measurement of 4-amino-10-methyl pteroyl glutamic acid (amethopterin) in plasma. J. Pharmacol. Exp. Ther.,120, 1–8.PubMedGoogle Scholar
  59. (59).
    Burchenal, J.H., Waring, G.B., Ellison, R.R. and Reilly, H.C. (1951): A simple method for determination of levels of amethopterin in blood and urine. Proc. Soc. Exp. Biol. Med.,78, 603–606.PubMedGoogle Scholar
  60. (60).
    Werkheiser, W.C., Zakrewski, S.F. and Nichol, C.A. (1962): Assay for 4-amino folic acid analogues by inhibition of folic acid reductase. J. Pharmacol. Exp. Ther.,137, 162–166.PubMedGoogle Scholar
  61. (61).
    Bohoun, C, Duprey, F. and Boudene, C. (1974): Radioimmunoassay of methotrexate in biological fluids. Clin. Chim. Acta,57, 263–267.CrossRefGoogle Scholar
  62. (62).
    Rasu, V. and Schreiber, R. (1975): A rapid and specific radioimmunoassay for methotrexate. Cancer Res.,35, 1047–1410.Google Scholar
  63. (63).
    Aherne, G.W., Piall, E., Marks, V., Schackman, S., Mould, G.P. and White, W.F. (1976): Radioimmunoassay of methotrexate and its clinical application. J. Clin. Path.,30, 97.Google Scholar
  64. 64).
    Hryniuk, W.M. and Bertino, J.R. (1969): Treatment of Leukemia with Large doses of Methotrexate and folinic acid: Clinical Biochemical correlates. J. Clin. Invest.,48, 2140–2155.CrossRefPubMedGoogle Scholar
  65. (65).
    Lacher, M. and Durant, J. (1965): Combined vinblastine and chlorambucil therapy of Hodgkins disease. Ann. Intern. Med.,62, 468–476.PubMedGoogle Scholar
  66. (66).
    Blum, R.H., Carter, S.K. and Agre, K. (1973): A clinical review of bleomycin—a new antineoplastic agent. Cancer,31, 903–914.CrossRefPubMedGoogle Scholar
  67. (67).
    Chabner, B.A., Myers, C.E., Coleman, C.N. and Johns D.G. (1975): The clinical pharmacology of antineoplastic agents. New Engl. J. Med.,292, 1159–1168.CrossRefPubMedGoogle Scholar
  68. (68).
    Ohnvma, T., Holland, J.F., Masuda, H., Wahgunda, J.A. and Goldberg, G.A. (1974): Microbiological assay of bleomycin: Inactivation, tissue distribution and clearance. Cancer,33, 1230–1238.CrossRefGoogle Scholar
  69. (69).
    Teale, J.D., Clough, J.M. and Marks, V. (1977): The measurement of plasma and urinary levels of bleomycin. Brit. J. Cancer,35, 822–827.PubMedGoogle Scholar
  70. (70).
    Broughton, A. and Strong, J.E. (1976): Radioimmunoassay of bleomycin. Cancer Res.,36, 1418–1421.PubMedGoogle Scholar
  71. (71).
    Van Vunakis, H., Langone, J.J., Riceberg, L.J. and Levine, L. (1974): Radioimmunoassay for adriamycin and daunomycin, Cancer Res.,34, 546–2552.Google Scholar
  72. (72).
    Chakraborty, J., English, J., Marks, V., Dumasia, M.C. and Chapman, D.J. (1976): A radioimmunoassay method for prednisolone: Comparison with the competitive binding method. Brit. J. Clin. Pharmacol.,3, 903–906.Google Scholar
  73. (73).
    Chang, P., Riggs, C.E., Scheerer, M.T., Wiernik, P.H. and Bachur, N.R. (1976): Combination chemotherapy with adriamycin and streptozotocin. II. Clinico pharmacologic correlation of augmented adriamycin toxicity caused by streptozocin. Clin. Pharmacol. Ther.,20, 611–616.PubMedGoogle Scholar
  74. (74).
    Brunk, S.F. and Delle, M. (1974): Morphine metabolism in man. Clin. Pharmacol. Ther.,16, 51–57.PubMedGoogle Scholar
  75. (75).
    Van Vunakis, H., Wassermann, E. and Levine, L. (1972): Specificity of antibodies to morphine, J. Pharmacol. Exp. Ther.,180, 514–521.PubMedGoogle Scholar
  76. (76).
    Morris, B.A., Robinson, J.D., Piall, E., Aherne, G.W. and Marks, V. (1974): Development of a radioimmunoassay for morphine having minimal cross-reactivity with codeine. J. Endocrinol.,64, 6–7.Google Scholar
  77. (77).
    Aherne, G.W., Marks, V., Morris, B.A., Piall, E.M., Robinson, J.D. and Twycross, R.G. (1975): The measurement of serum morphine levels by radioimmunoassay following oral administrations of diamorphine or morphine. Brit. J. Pharmacol.,54, 228P-229P.Google Scholar
  78. (78).
    Adler, T.K., Fujimoto, J.M., Way, L.E. and Baker, M.E. (1955): Metabolic fate of codeine in man. J. Pharmacol. Exp. Ther.,114, 251–262.PubMedGoogle Scholar
  79. (79).
    Spector, S. and Flynn, E.J. (1971): Barbiturates: Radioimmunoassay. Science,174, 1037–1039.Google Scholar
  80. (80).
    James, K.R., Singh, P., Leung, D.K., Monken, C.E. and Schneider, R.S. (1976): Homogenous enzyme immunoassay for carbamazepine in serum. Clin. Chem.,22, 1185.Google Scholar
  81. (81).
    Peskar, B. and Spector, S. (1973): Quantitative determination of diazepam in blood by radioimmunoassay. J. Pharmacol. Exp. Ther.,186, 167–172.PubMedGoogle Scholar
  82. (82).
    Dixon, W.R., Young, R.L., Ning, R. and Liebman, A. (1977): Radioimmunoassay of the anticonvulsant agent clonazepam. J. Pharm. Sci.,66, 235–237.CrossRefPubMedGoogle Scholar
  83. (83).
    Cook, C.E., Kepler, J.A. and Christensen, D.H. (1973): Antiserum to diphenylhydantoin; Preparation and characterisation. Res. Commun. Chem. Path. Pharmacol.,5, 767–774.Google Scholar
  84. (84).
    Pippinger, C.E., Sichler, D.L. and Lichtblau, L. (1974): Preliminary clinical evaluation of an experimental enzyme immunoassay system for DPH and phenobarbital in serum. Clin. Chem.,20, 869.Google Scholar
  85. (85).
    Montgomery, M.R., Holtzman, J.L., Leute, R.K., Dewees, J.S. and Bolz, G. (1975): Determination of diphenyldantoin in human serum by spin immunoassay. Clin. Chem.,21, 221–226.PubMedGoogle Scholar
  86. (86).
    Orme, M.L., Borga, O., Cook, C.E. and Sjöqvist (1976): Measurement of diphenylhydantoin in 0.1-ml plasma samples: Gas chromatography and radioimmunoassay compared. Clin. Chem.,22, 246–249.Google Scholar
  87. (87).
    Robinson, J.D., Morris, B.A., Aherne, G.W. and Marks, V. (1975): Pharmacokinetics of a single dose of phenytoin in man measured by radioimmunoassay. Brit. J. Clin. Pharmacol.,2, 345–349.Google Scholar
  88. (88).
    Reynolds, E.H., Chadwick, D. and Galbraith, A.W. (1976): One drug (phenytoin) in the treatment of epilepsy. Lancet,1, 923–926.CrossRefPubMedGoogle Scholar
  89. (89).
    Teale, J.D., Forman, E.J., King, L.J. and Marks, V. (1974): Radioimmunoassay of cannabinoids in blood and urine. Lancet,2, 553–555.CrossRefPubMedGoogle Scholar
  90. (90).
    Teale, J.D., Forman, E.J., King, L.J., Piall, E.M. and Marks, V. (1975): The development of a radioimmunoassay for cannabinoids in blood and urine. J. Pharm. Pharmacol.,27, 465–472.PubMedGoogle Scholar
  91. (91).
    Marks, V., Teale, J.D. and King, L.J. (1976): Radioimmunoassays of cannabis products in blood and urine, in Marihuana; Chemistry, Biochemistry and Cellular Effects, ed. Nahas, G.G., Springer Verlag, N.Y., p. 71–85.Google Scholar
  92. (92).
    Teale, D. and Marks, V. (1976): A fatal motor-car accident and cannabis use. Investigation by radioimmunoassay. Lancet,1, 884–885.CrossRefPubMedGoogle Scholar
  93. (93).
    Garrett, C.P.O., Braithwaite, R.A. and Teale, J.D. (1977): An unusual case of tetrahydrocannabinol intoxication confirmed by radioimmunoassay. Brit. Med. J.,2, 166.CrossRefPubMedGoogle Scholar
  94. (94).
    Robinson, J.D., Morris, B.A. and Marks, V. (1975): Development of a radioimmunoassay for etorphine. Res. Comm. Chem. Path. Pharmacol.,10, 1–8.Google Scholar
  95. (95).
    Aherne, G.W., Piall, E.M., Robinson, J.D., Morris, B.A. and Marks, V. (1975): Two applications of a radioimmunoassay for morphine. In “Radioimmunoassay in Clinical Biochemistry”, ed. Pasternak, C.A., pp. 81–90. Heyden & Sons Ltd., London.Google Scholar
  96. (96).
    English, J., Chakraborty, J., Marks, V. and Parke, A. (1975): A radioimmunoassay procedure for dexamethasone. Plasma and urine levels in man. Europ. J. Clin. Pharmacol.9, 239–244.CrossRefGoogle Scholar
  97. (97).
    Marks, V., Mould, G.P., Morris, B.A., Stout, G. and Williams, S. (1978): The development of a radioimmunoassay for propranolol in biological fluids. Brit. J. Clin. Pharmacol., 5, (in press).Google Scholar

Copyright information

© Springer-Verlag 1977

Authors and Affiliations

  • G. P. Mould
    • 1
  • G. W. Aherne
    • 1
  • B. A. Morris
    • 1
  • J. D. Teale
    • 1
  • V. Marks
    • 1
  1. 1.Department of Clinical BiochemistryUniversity of SurreyGuildfordU.K.
  2. 2.Clinical Pharmacy SectionSt. Like’s HospitalGuildfordU.K.

Personalised recommendations